Tuesday, June 18, 2024

Roche’s Groundbreaking FDA-Approved HPV Self-Collection Solution

Similar articles

Roche announced a significant advancement in women’s health with the Food and Drug Administration (FDA) approval of its innovative human papillomavirus (HPV) self-collection solution. This new tool is one of the first of its kind available in the United States, empowering women to take proactive steps in cervical cancer prevention by allowing private, self-administered sample collection.

Statistics reveal that over half of the cervical cancer cases in the U.S. arise from patients who are underscreened. This underscores a critical need for accessible cancer screening options that can reduce barriers to testing and facilitate early detection and treatment. Annually, over 13,000 women are diagnosed with cervical cancer in the U.S., and approximately 4,000 succumb to this largely preventable disease due to HPV infection.

Roche’s self-collection solution is set to transform cervical cancer screening by making it more accessible. Women can now collect their vaginal samples privately in a healthcare setting. These samples are then analyzed using Roche’s advanced cobas® molecular testing instruments. For those who test positive for HPV, follow-up care with healthcare providers is seamlessly facilitated.

Roche’s HPV Self-Collection Kit: A Step Towards Eliminating Cervical Cancer by 2030

Matt Sause, CEO of Roche Diagnostics, highlighted the alignment of this innovation with the WHO’s ambitious goal of eliminating cervical cancer by 2030. He emphasized, “With vaccinations, innovative diagnostic tools, and screening programs, achieving the WHO’s goal is within reach. Our HPV self-collection solution supports this by reducing barriers and expanding access to HPV screening.”

The introduction of this solution is particularly timely as more than half of the patients diagnosed with cervical cancer in the U.S. have never been screened or only infrequently so. Factors such as limited healthcare access, social and economic barriers, cultural concerns, and previous traumatic experiences often deter women from participating in routine screenings. Roche’s self-collection kit is designed to mitigate these issues by providing an alternative to traditional clinician-led procedures, thus offering privacy and reducing discomfort or embarrassment that can accompany such tests.

Roche has also collaborated with the National Cancer Institute (NCI) as part of the National Institutes of Health (NIH) on the Cervical Cancer “Last Mile” Initiative. This public-private partnership was instrumental in navigating the regulatory pathways leading to this FDA approval, showcasing a successful model of collaboration in the healthcare sector.


Roche Enhances Cervical Cancer Detection with Comprehensive HPV Testing Solutions

Roche’s commitment to combating cervical cancer extends beyond this new product. The company’s portfolio includes the cobas HPV Test, which is a primary screening tool used to detect 14 types of high-risk HPV genotypes known to increase the risk of cervical cancer. This test provides specific results for HPV 16, HPV 18, and twelve other high-risk pooled genotypes.

Moreover, Roche’s automated cobas systems, such as the 4800, 5800, 6800, and 8800 models, deliver rapid results—offering capabilities to process up to 1,056 tests in an eight-hour shift. The portfolio also features CINtec PLUS Cytology and CINtec® Histology, the only FDA-cleared products that help pathologists confirm the presence of pre-cancerous cervical lesions.

You can follow our news on our Telegram and LinkedIn accounts.

The IMPACT trial, which validated the clinical benefits of Roche’s cervical cancer portfolio, included diverse patient segments, ensuring that the testing solutions are effective across different demographics, particularly those at higher risk of HPV.


Resource: Roche, May 15, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article